Drug Discovery

Ferring Pharmaceuticals to buy US firm Rebiotix

Switzerland-based Ferring Pharmaceuticals has agreed to acquire US clinical stage biotechnology firm Rebiotix for an undisclosed sum.

Eidos Therapeutics raises $64m for transthyretin amyloidosis therapy

Eidos Therapeutics has completed $64m in Series B funding to support phase 2 clinical trials of AG10, a best-in-class therapy for transthyretin amyloidosis, and ongoing preparation for phase 3 clinical trials.

Roche acquires Inception neuroscience program

Roche has acquired the Inception 5 program, which is focused on regenerative therapies for multiple sclerosis.

Pfizer to hold 25% ownership stake in Allogene Therapeutics

Pfizer has signed an asset contribution agreement with Allogene Therapeutics for its Allogeneic CAR T immuno-oncology portfolio.

Actinium Pharmaceuticals, Astellas collaborate on AWE platform technology

Actinium Pharmaceuticals has entered into a research and option agreement with Astellas Pharma to develop Actinium-225 Radio-Conjugates (ARCs) using its Actinium Warhead Enabling (AWE) platform technology.

Takeda mulls bid for biopharmaceutical firm Shire

Japanese drugmaker Takeda said it is considering a possible offer for the acquisition of Shire, Irish-headquartered global specialty biopharmaceutical company.

Chinese biotech company Adagene raises $50m in new funding round

Adagene, an antibody discovery and development company, has raised $50m in Series C financing, led by Sequoia China, and backed by New World TMT, AVIC Trust, King Star Capital, Gopher Asset Management and other investors.

Redx Pharma signs option and licence deal for anti-infective program with Deinove

Deinove has signed a license option agreement with the British compan yRedx Pharma to acquire its anti-infective program, Novel Bacterial Topoisomerase Inhibitor (NBTI), which targets Gram-negative infections.

Regeneron, Alnylam partner to discover new treatments for NASH

Regeneron Pharmaceuticals and Alnylam Pharmaceuticals have entered into collaboration to identify RNAi therapeutics for the chronic liver disease nonalcoholic steatohepatitis (NASH) and potentially other related diseases.